Tae-hoon H. Chung

#13-01G, 14 Medical Drive
Singapore, 117599, Singapore

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications

Risk factors and their contributions to prognosis in multiple myeloma.

Risk factors and their contributions to prognosis in multiple myeloma.

Journal: Haematologica
Published: November 17, 2025

Superenhancer-driven SMC4 promotes myeloma growth by epigenetically enhancing IFI16-dependent STING signaling.

Superenhancer-driven SMC4 promotes myeloma growth by epigenetically enhancing IFI16-dependent STING signaling.

Journal: Apoptosis : an international journal on programmed cell death
Published: October 06, 2025

The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma.

The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma.

Journal: Blood
Published: February 28, 2024

Deciphering MARCH5's impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling.

Deciphering MARCH5's impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling.

Journal: Blood neoplasia
Published: January 08, 2024

Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma.

Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma.

Journal: Nature communications
Published: June 30, 2023

Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma.

Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma.

Journal: Haematologica
Published: May 02, 2023

Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma.

Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma.

Journal: Cancer research
Published: November 04, 2022

Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS.

Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS.

Journal: Haematologica
Published: September 09, 2021

p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain).

p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain).

Journal: Oncogene
Published: August 30, 2021

Genomic characterization of functional high-risk multiple myeloma patients.

Genomic characterization of functional high-risk multiple myeloma patients.

Journal: Blood cancer journal
Published: July 18, 2021

Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma.

Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma.

Journal: Journal for immunotherapy of cancer
Published: May 08, 2021

Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma.

Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma.

Journal: Cancer research
Published: March 25, 2021
Showing 1-12 of 34

Last Updated: 09/26/2026